⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters

Official Title: A Multicenter Prospective Randomized Controlled Trial of Thrombosis Prophylaxis With Warfarin in Cancer Patients With Central Venous Catheters

Study ID: NCT00024297

Conditions

Thromboembolism

Interventions

warfarin

Study Description

Brief Summary: RATIONALE: Warfarin may be effective in preventing the formation of blood clots in patients with central venous catheters. PURPOSE: Randomized clinical trial to study the effectiveness of warfarin in preventing blood clots in cancer patients who have central venous catheters.

Detailed Description: OBJECTIVES: * Determine the utility of warfarin in reducing thrombosis rates in cancer patients with central venous catheters. * Compare the thrombosis rates in patients treated with different warfarin dosing schedules. * Compare the adverse events and survival of patients receiving or not receiving this drug. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to sclerosant potential of cytotoxic regimen (low vs high), site of placement of catheter (peripheral vs central), and duration of drug administration (brief infusion (under 24 hours) vs prolonged infusion (24 hours and over)). Patients are randomized to 1 of 3 arms. * Arm I: Patients receive no warfarin. * Arm II: Patients receive oral warfarin daily beginning 3 days before placement of central venous catheter (CVC) and continuing until CVC is removed or thrombosis occurs. * Arm III: Patients receive oral warfarin as in arm II, with dose adjustment after CVC placement to achieve and maintain INR level. Patients are followed at 12 months. PROJECTED ACCRUAL: A total of 1,400 patients (400 in arm I, 700 in arm II, and 300 in arm III) will be accrued for this study within 2 years.

Eligibility

Minimum Age: 16 Years

Eligible Ages: CHILD, ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Queen Elizabeth Hospital at University of Birmingham, Birmingham, England, United Kingdom

City Hospital - Birmingham, Birmingham, England, United Kingdom

Birmingham Heartlands and Solihull NHS Trust -Teaching, Birmingham, England, United Kingdom

Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom

Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom

Cumberland Infirmary, Carlisle, England, United Kingdom

Cheltenham General Hospital, Cheltenham, England, United Kingdom

Essex County Hospital, Colchester, England, United Kingdom

Royal Devon and Exeter Hospital, Exeter, England, United Kingdom

Diana Princess of Wales Hospital, Grimsby, England, United Kingdom

St. Luke's Cancer Centre at Royal Surrey County Hospital, Guildford, England, United Kingdom

Huddersfield Royal Infirmary, Huddersfield, West Yorks, England, United Kingdom

Princess Royal Hospital, Hull, England, United Kingdom

Ipswich Hospital NHS Trust, Ipswich, England, United Kingdom

Royal Lancaster Infirmary, Lancaster, England, United Kingdom

Cookridge Hospital at Leeds Teaching Hospital NHS Trust, Leeds, England, United Kingdom

Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom

Guy's and St. Thomas' Hospitals NHS Foundation Trust, London, England, United Kingdom

St. George's Hospital, London, England, United Kingdom

Charing Cross Hospital, London, England, United Kingdom

Clatterbridge Centre for Oncology NHS Trust, Merseyside, England, United Kingdom

South Tees Hospitals NHS Trust, Middlesbrough, Cleveland, England, United Kingdom

Northern Centre for Cancer Treatment at Newcastle General Hospital, Newcastle-Upon-Tyne, England, United Kingdom

Mount Vernon Hospital, Northwood, England, United Kingdom

Royal Preston Hospital, Preston, England, United Kingdom

Oldchurch Hospital, Romford, England, United Kingdom

Royal South Hants Hospital, Southampton, England, United Kingdom

Sandwell General Hospital, West Bromwich, England, United Kingdom

Good Hope Hospital Trust, West Midlands, England, United Kingdom

Airedale General Hospital, West Yorkshire, England, United Kingdom

Royal Hampshire County Hospital, Winchester, England, United Kingdom

New Cross Hospital, Wolverhampton, England, United Kingdom

Worcester Royal Hospital, Worcester, England, United Kingdom

Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom

Royal Infirmary - Castle, Glasgow, Scotland, United Kingdom

Velindre Cancer Center at Velinde Hospital, Cardiff, Wales, United Kingdom

Singleton Hospital, Swansea, Wales, United Kingdom

Plymouth Hospitals NHS Trust, Plymouth, , United Kingdom

Contact Details

Name: Annie Young

Affiliation: University Hospital Birmingham

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: